Impact of vomiting on P2Y12 platelet inhibition in patients with ST-elevation myocardial infarction: A prespecified subanalysis of the ON-TIME 3 trial
Publication date
2022-01
Authors
ON-TIME 3 investigators
Editors
Advisors
Supervisors
Document Type
Letter
Metadata
Show full item recordCollections
License
taverne
Abstract
Vomiting is associated with lower levels of ticagrelor concentration and higher platelet reactivity in the early hours of ST-elevation myocardial infarction. These results support reloading with a ticagrelor loading dose and/or treatment with intravenous platelet inhibitors when patients vomit.
Keywords
Taverne, Cardiology and Cardiovascular Medicine
Citation
ON-TIME 3 investigators 2022, 'Impact of vomiting on P2Y12 platelet inhibition in patients with ST-elevation myocardial infarction : A prespecified subanalysis of the ON-TIME 3 trial', American Heart Journal, vol. 243, pp. 39-42. https://doi.org/10.1016/j.ahj.2021.08.011